SCHEMBL6583934

SCHEMBL6583934

Cc1ccc(N)c2cc(O)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 3/20 0.49
ALDH1A1 P00352 6/20 0.43
CYP3A4 P08684 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
RECQL P46063 2/20 0.43
ALOX15 P16050 2/20 0.43
THRB P10828 1/20 0.43
HIF1A Q16665 1/20 0.43
ACHE P22303 1/20 0.41
KDM4E B2RXH2 3/20 0.39
GLA P06280 2/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 2/20 0.39
CASP1 P29466 3/20 0.39
TSHR P16473 3/20 0.39
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30783551 1.00 GLO1 (0.49) GLO1ALDH1A1CYP3A4TDP1RECQL
SCHEMBL29771848 0.78 OPRK1 (0.44) ALDH1A1CYP3A4TDP1RECQLALOX15
SCHEMBL1562746 0.78 ALDH1A1 (0.56) ALDH1A1CYP3A4TDP1ALOX15THRB
SCHEMBL8923992 0.78 OPRK1 (0.44) ALDH1A1CYP3A4TDP1RECQLALOX15
SCHEMBL6582947 0.75 AXL (0.46) GLO1ALDH1A1CYP3A4TDP1RECQL
SCHEMBL30783555 0.75 AXL (0.46) GLO1ALDH1A1CYP3A4TDP1RECQL
SCHEMBL30783550 0.75 AXL (0.46) GLO1ALDH1A1CYP3A4TDP1RECQL
SCHEMBL63944 0.75
SCHEMBL37147038 0.75
SCHEMBL4870452 0.75 CYP3A4 (0.61) ALDH1A1CYP3A4TDP1RECQLALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259875-A1 Amine derivatives BAYER HEALTHCARE AG (DE) 2004-12-23 US disclosed
EP-1414788-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS Bayer HealthCare AG (DE) 2004-05-06 EP disclosed
WO-2003014064-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS BAYER HEALTHCARE AG (DE) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259875-A1 Amine derivatives AVPR1A, GRIN1, OPRL1 GLO1 2844/4885ALDH1A1 714/4885CYP3A4 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.